Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Straggler Novavax Still Hopes To Hit Paydirt With Combo Vaccine

Executive Summary

The company announced early data for a combination vaccine against SARS-CoV-2 and influenza, which could provide a revenue opportunity of $2bn.

You may also be interested in...



US FDA To Publish Advisory Committee Timeline For COVID-19 Vaccine In Children Under 5

But CBER Director Peter Marks reiterated to Senators that EUAs cannot be granted for those children until applications are completed and submitted.

J&J Continues Signaling Aggressive M&A Approach To Drive Growth

Johnson & Johnson reported disappointing Q1 sales for its COVID-19 vaccine but called the Carvykti launch solid and discussed plans for further diversification of its multiple myeloma portfolio.

Moderna Looks To Catch Up In COVID-19 For Kids, While Still Branching Out In Other Areas

The company hopes to expand Spikevax’s reach beyond the current approved population while also looking to take the lead in mRNA vaccines in other diseases.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC146267

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel